Clinical significance of the circle of Willis in intracranial atherosclerotic stenosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kang Min | - |
dc.contributor.author | Kang, Hyun-Seung | - |
dc.contributor.author | Lee, Woong Jae | - |
dc.contributor.author | Cho, Young Dae | - |
dc.contributor.author | Kim, Jeong Eun | - |
dc.contributor.author | Han, Moon Hee | - |
dc.date.accessioned | 2023-03-08T17:51:26Z | - |
dc.date.available | 2023-03-08T17:51:26Z | - |
dc.date.issued | 2016-03 | - |
dc.identifier.issn | 1759-8478 | - |
dc.identifier.issn | 1759-8486 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/64303 | - |
dc.description.abstract | Introduction The effectiveness of a scoring system based on the circle of Willis for evaluations of collateral circulation was studied in patients with intracranial atherosclerotic stenosis. Methods Eighty-three patients who underwent medical or endovascular treatment for symptomatic and severe intracranial atherosclerotic stenosis were enrolled in the study. Clinical profiles, status of the circle of Willis (poor and good integrity group), and clinical outcomes were analyzed. Primary endpoints were: (1) symptomatic ischemic or hemorrhagic stroke within 30days; and (2) recurrent transient ischemic attack or ischemic stroke beyond 30days. Results The estimated rates of the primary endpoint at 1 and 2years after treatment were 8.5% and 11.4% in the medical group and 7.0% and 9.7% in the endovascular group, respectively. A primary endpoint event after medical treatment was only identified in patients with poor integrity of the circle of Willis (p=0.059). In patients with poor integrity of the circle of Willis, previous antiplatelet medication before initial presentation (p=0.026) and hypertension (p=0.006) were more prevalent. During the follow-up period, complete arterial occlusion was identified in 9 patients. The circle of Willis score of the patients with complete arterial occlusion was 1.331.52 in the fatal stroke group (n=3) and 3.20 +/- 1.64 in the asymptomatic group (n=6, p=0.099). Conclusions If patients have poor integrity of the circle of Willis, the risk of recurrent stroke may be increased. Such patients appear to be good candidates for endovascular treatment. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BMJ PUBLISHING GROUP | - |
dc.title | Clinical significance of the circle of Willis in intracranial atherosclerotic stenosis | - |
dc.type | Article | - |
dc.identifier.doi | 10.1136/neurintsurg-2014-011439 | - |
dc.identifier.bibliographicCitation | JOURNAL OF NEUROINTERVENTIONAL SURGERY, v.8, no.3, pp 251 - 255 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000371327000012 | - |
dc.identifier.scopusid | 2-s2.0-84958590634 | - |
dc.citation.endPage | 255 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 251 | - |
dc.citation.title | JOURNAL OF NEUROINTERVENTIONAL SURGERY | - |
dc.citation.volume | 8 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Angioplasty | - |
dc.subject.keywordAuthor | Atherosclerosis | - |
dc.subject.keywordAuthor | Stroke | - |
dc.subject.keywordAuthor | Stenosis | - |
dc.subject.keywordPlus | AGGRESSIVE MEDICAL THERAPY | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | RISK | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Neuroimaging | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.